Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor
The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of: a) a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein R 1 -R 4 , p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.
1 . A method of treating lung cancer in a patient comprising administering to the patient therapeutically effective amounts of:
a) a compound of the formula I:
or a pharmaceutically acceptable salt thereof and an erbB-1 inhibitor
2 . The method of claim 1 wherein a tumor cell from said lung cancer expresses cMET.
3 . The method of claim 1 , wherein a tumor cell from said lung cancer overexpresses erbB-1.
4 . The method of claim 1 wherein said erbB-1 inhibitor comprises a compound of formula III:
or a pharmaceutically acceptable salt thereof
5 . The method of claim 1 wherein said erbB-1 inhibitor comprising a compound of Formula IV:
or a pharmaceutically acceptable salt thereof.
6 . The method of claim 1 , wherein said lung cancer is resistant to Formula III.
7 . The method of claim 1 , wherein said lung cancer is resistant to Formula IV.
8 . The method of claim 1 , wherein said compound of Formula I and said erbB-1 inhibitor have a synergistic effect in inhibiting growth of said lung cancer.
9 . The method of claim 1 wherein a tumor cell from said lung cancer expresses AXL.
10 . The method of claim 9 , wherein the tumor cell overexpresses AXL.
11 . A method of treating cancer in a patient in need thereof, comprising identifying if a tumor cell from said cancer expresses or overexpresses AXL and if said tumor cell expresses or overexpresses AXL administering a composition comprising Formula I and an erbB-1 inhibitor to said patient.
12 . The method of claim 11 wherein said cancer is resistant to gefitinib.
13 . The method of claim 11 wherein said cancer is resistant to erlotinib.
14 . The method of claim 11 , wherein said erb-B1 inhibitor is erlotinib or a pharmaceutically acceptable salt thereof.
15 . The method of claim 11 , wherein said erb-B1 inhibitor is gefitinib or a pharmaceutically acceptable salt thereof.
16 . The method of claim 11 wherein said cancer is lung cancer